Medigene AG: Medigene's Academic Partners Provide Update on Planned MAGE-A1-specific TCR Clinical IIT during CIMT

Planegg (pta007/08.05.2018/07:30 UTC+2) Medigene AG (MDG1, Frankfurt, Prime Standard), announced that researchers from Max-Delbrück-Center for Molecular Medicine (MDC) and Charité, both in Berlin, Germany, will present an update on the clinical trial preparations concerning a MAGE-A1-specific T cell receptor clinical investigator-initiated trial (IIT) at the 16th Cancer Immunotherapy Conference (CIMT) in Mainz, Germany, from 15 - 17 May. CIMT is Europe's largest meeting focused on cancer immunotherapy research and development.

In the abstract that will be published today, the partners announce that the competent regulatory authority Paul-Ehrlich-Institute, Germany, has granted the clinical trial authorization for the planned Phase I trial and that the manufacturing license for the established GMP-compliant manufacturing process is expected to be issued in Q2 2018. More details on the trial design for the treatment of patients with relapsed or refractory multiple myeloma can be found in the abstract on the CIMT website: http://www.meeting.cimt.eu/program

The academic trial will be conducted under the responsibility of Charité and the Max-Delbrück Center. Medigene has supported both the MDC and Charité in regulatory affairs and other matters related to trial approval. Additionally, Medigene has certain rights of first negotiation for the TCR candidate utilized in this trial.

Independently, Medigene is currently conducting its own, company-sponsored phase I/II clinical trial with its proprietary TCR therapy MDG1011 in various blood cancer indications which commenced at the end of March 2018.

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development. For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
email: investor@medigene.com

Contact Trial Sponsor
Charité - Universitätsmedizin Berlin
Chariteplatz 1, 11017 Berlin, Germany

Sponsor representative:
Prof. Dr. rer. nat. Thomas Blankenstein
Phone: +49 (0)30 450 513601
E-Mail: tblanke@mdc-berlin.de

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 33 3301
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate